Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Sex Transm Dis. 2010 May;37(5):290–297. doi: 10.1097/OLQ.0b013e3181d3d023

Table 1.

Prophylactic-vaccine efficacies expected to be an output of vaccine randomized controlled trials [1, 2].

Vaccine efficacy Definition
VES Vaccine efficacy of reducing susceptibility: the relative reduction in risk of acquisition due to vaccination is given by 1 − VES
VEP Vaccine efficacy of reducing shedding frequency: the relative reduction in the shedding frequency (given infection) due to prophylactic vaccination is given by 1 − VEP
VEI Vaccine efficacy of reducing infectivity during shedding episodes: the relative reduction in transmission probability per discordant partnership due to prophylactically vaccinating the index partner (given his/her infection and shedding) is given by 1 − VEI
1

Stanberry, LR (2004) Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11 Suppl 3: 161A–169A.

2

http://clinicaltrials.gov/ct2/show/NCT00057330 (2009) HerpeVac Trial for Young Women.